Inhibition of hepatitis c virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 7064-7074

  Lee, Chang Ho ^a   Lee, Young Ju ^a   Kim, Ji Hyun ^a   Lim, Jong Hoon ^a   Kim, Jung Hye ^a   Han, Wonkyo ^b   Lee, Soo Han ^c   Noh, Gyu Jeong ^c   Lee, Seong Wook ^a  

^a Dankook University   (South Korea)

^b BexCoreInc   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2' FLUOROPYRIMIDINE RNA APTAMER; 2' HYDROXYL RNA APTAMER; APTAMER; NONSTRUCTURAL PROTEIN 5B; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; VIRUS GENOME; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; APTAMERS, NUCLEOTIDE; BINDING, COMPETITIVE; CELL LINE, TUMOR; HEPACIVIRUS; HEPATOCYTES; HUMANS; MALE; MICE; MICE, INBRED BALB C; RNA REPLICASE; SELEX APTAMER TECHNIQUE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS; MUS;

EID: 84878614308     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00405-13     Document Type: Article

References (55)

1. Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N. Engl. J. Med. 345:41-52.
2. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13:2436 -2441.
3. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76:5974 -5984.
4. Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81:1631-1648.
5. Moradpour D, Brass V, Gosert R, Wolk B, Blum H. 2002. Hepatitis C: molecular virology and antiviral targets. Trends Mol. Med. 8:476-482.
6. Pawlotsky JM. 2011. Treatment failure and resistance with direct-acting antiviral drug against hepatitis C virus. Hepatology 53:1742-1751.
7. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
8. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
9. Que-Gewirth NS, Sullenger BA. 2007. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14:283-291.
10. Kaur G, Roy I. 2008. Therapeutic applications of aptamers. Expert Opin. Invest. Drugs 17:43- 60.
11. Sumpter R, Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79:2689 -2699.
12. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
13. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190.
14. Lohmann V, Korner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110 -113.
15. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
16. Lee CH, Kim JH, Kim HW, Myung HJ, Lee SW. 2012. Hepatitis C virus replication-specific inhibition of microRNA activity with self-cleavable allosteric ribozyme. Nucleic Acid Ther. 22:17-29.
17. Niranjanakumari S, Lasda E, Brazas R, Garcia-Blanco MA. 2002. Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 26:182-190.
18. Chang BY, Lee CH, Lee JH, Lee SW. 2010. Comparative analysis of intracellular inhibition of hepatitis C virus replication by small interfering RNAs. Biotechnol. Lett. 32:1231-1237.
19. Shibutani M. 2000. Anesthesia, artificial ventilation and perfusion fixation, p 511-521. In Krinke GJ (ed), The laboratory rat. Academic Press, New York, NY.
20. Behrens SE, Tomei L, Francesco RD. 1996. Identification and properties of the RA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
21. Luo G, Hamatake RK, Mathis DM, Racela J, Rigat KL, Lemm J, Colonno RJ. 2000. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 74:851-863.
22. Paul CP, Good PD, Li SX, Kleihauer A, Rossi JJ, Engelke DR. 2003. Localized expression of small RNA inhibitors in human cells. Mol. Ther. 7:237-247.
23. Bae SJ, Oum JH, Sharma S, Park J, Lee SW. 2002. In vitro selection of specificRNAinhibitors of NFATc. Biochem. Biophys. Res. Commun. 298: 486-492.
24. Hwang BH, Cho JS, Yeo HJ, Kim JH, Chung KM, Han KS, Jang SK, Lee SW. 2004. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10:1277-1290.
25. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
26. Healy JM, Lewis SD, Kurz M, Boomer RM, Thompson KM, Wilson C, McCauley TG. 2004. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21:2234 -2246.
27. de Smidt PC, Le Doan T, de Falco S, van Berkel TJ. 1991. Association of antisense oligonucleotides with lipoproteins prolongs the plasma halflife and modifies the tissue distribution. Nucleic Acids Res. 19:4695- 4700.
28. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. 2005. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685- 6899.
29. Plank C, Zatloukal K, Cotton M, Mechtler K, Wagner E. 1992. Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug. Chem. 3:533-539.
30. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25:1149 -1157.
31. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR. 2008. Structural basis of toll-like receptor 3 signaling with doublestranded RNA. Science 320:379 -381.
32. Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, Fitzgerald KA, Samokhin AO, Wang Y, Sayers S, Aikawa M, Jerome WG, Ostrowski MC, Bromme D, Libby P, Tabas IA, Welch CL, Tall AR. 2009. Free cholesterol accumulation in macrophage membranes activates toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ. Res. 104:455- 465.
33. Azzam KM, Fessler MB. 2012. Crosstalk between reverse cholesterol transport and innate immunity. Trends Endocrinol. Metab. 23:169 -178.
34. Wada S, Obika S, Shibata MA, Yamamoto T, Nekatani M, Yamaoka T, Torigoe H, Harada-Shiba M. 2012. Development of a 2=,4=-BNA/LNAbased siRNA for dyslipidemia and assessment of the effects of its chemical modifications in vivo. Mol. Ther. Nucleic Acids 1:e45. doi:10.1038/mtna .2012.32.
35. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294 -9299.
36. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
37. Ryu KJ, Kim JH, Lee SW. 2003. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry siteexpressing cells by targeted trans-splicing. Mol. Ther. 7:386 -395.
38. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S. 2010. RNAi as a new therapeutic strategy against HCV. Biotechnol. Adv. 28:27-34.
39. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198 -201.
40. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. 2011. MicroRNA- 122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5'UTR. Proc. Natl. Acad. Sci. U. S. A. 108:4991- 4996.
41. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. 2007. Cyclin G1 Is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67:6092- 6099.
42. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. 2009. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49:1571- 1582.
43. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. 2012. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122:2884 -2897.
44. Huang DB, Vu D, Cassiday LA, Zimmerman JM, Maher III, Ghosh LJG. 2003. Crystal structure of NF-kB (p50)2 complexed to a high-affinity RNA aptamer. Proc. Natl. Acad. Sci. U. S. A. 100:9268 -9273.
45. Ghosh G, Huang DB, Huxford T. 2004. Molecular mimicry of the NF-kB DNA target site by a selected RNA aptamer. Curr. Opin. Struct. Biol. 14:21-27.
46. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1975.
47. Grobler JA, Markel EJ, Fay JF, Graham DJ, Simcoe AL, Ludmerer SW, Murray EM, Migliaccio G, Flores OA. 2003. Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase. J. Biol. Chem. 278:16741-16746.
48. Sohlenius-Sternbeck AK. 2006. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol. In Vitro 20:1582-1586.
49. Chang M, Williams O, Mittler J, Quintanilla A, Carithers RL, Jr, Perkins J, Corey L, Gretch DR. 2003. Dynamics of hepatitis C virus replication in human liver. Am. J. Pathol. 163:433- 444.
50. Bellecave P, Andreola ML, Ventura M, Tarrago-Litvak L, Litvak S, Astier-Gin T. 2003. Selection of DNA aptamers that bind the RNAdependent RNA polymerase of hepatitis C virus and inhibit viral RNA synthesis in vitro. Oligonucleotides 13:455- 463.
51. Biroccio A, Hamm J, Incitti I, Francesco RD, Tomei L. 2002. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76:3688 -3696.
52. Jones LA, Clancy LE, Rawlinson WD, White PA. 2006. High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob. Agents Chemother. 50:3019 -3027.
53. Bellecave P, Cazenave C, Rumi J, Staedel C, Cosnefroy O, Andreola ML, Ventura M, Tarrago-Litvak L, Astier-Gin T. 2008. Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob. Agents Chemother. 52:2097-2110.
54. Long SB, Long MB, White RR, Sullenger BA. 2008. Crystal structure of an RNA aptamer bound to thrombin. RNA 14:2504 -2512.
55. Bukh J. 2012. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 142:1279 -1287.e3.